Enlivex completes enrollment for GVHD in transplant

September 2011
Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p5
Trade Publication
The article reports on biotechnology firm Enlivex Therapeutics' completion of enrollment for its Phase I/II clinical trials for the treatment of graft versus host disease (GVHD) in bone marrow transplant patients in Israel. The company is expecting to recruit about 12 patients in the next three months of 2011. The trial is also relevant to patients with autoimmune diseases. Comments from Enlivex chief executive officers (CEO) Alon Moran are provided.


Related Articles

  • Response as an end point in treatment trials for acute GVHD. Pavletic, S Z // Bone Marrow Transplantation;Feb2012, Vol. 47 Issue 2, p161 

    The author argues on that the studies have provided data that suggest day 28 as a suitable time point in measuring the response to first-line therapy in clinical trials for acute graft versus host disease (GVHD). The author stresses that the studies support the expert panel endorsement of day 28...

  • Subnormal androgen levels in young female bone marrow transplant recipients with ovarian dysfunction, chronic GVHD and receiving glucocorticoid therapy. Saarinen-Pihkala, U. M.; Taskinen, M.; Wikström, A. M.; Dunkel, L.; Hovi, L. // Bone Marrow Transplantation;Mar2004, Vol. 33 Issue 5, p503 

    Summary:Ovarian function and sex hormone production with special focus on androgens (testosterone, androstenedione, dehydroepiandrosterone and its sulfate, DHEAS) was followed up during 1.5-20 (mean 9) years after bone marrow transplantation (BMT) in 24 female subjects aged 16-33 (mean 21) years...

  • Osiris Targets GVHD With Stem Cell Therapy.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5 

    The article reports that Osiris Therapeutics Inc. is moving forward with a Phase III pivotal trial of its mesenchymal stem cell therapy Prochymal following the success of its Phase II trial in the U.S. The Prochymal is believed to be the first-line agent to treat acute graft-versus-host disease...

  • Extracorporeal photopheresis in chronic graft-versus-host disease. Foss, FM; Gorgun, G; Miller, KB // Bone Marrow Transplantation;5/1/2002, Vol. 29 Issue 9, p719 

    Focuses on extracorporeal photopheresis (ECP), a novel therapeutic intervention which has demonstrated efficacy in patients with refractory acute and chronic graft-versus-host disease (cGVHD). Information on extracorporeal phototherapy; Mechanism of action of ECP; Effects of ECP on lymphocytes,...

  • ENZO BIOCHEM TREATMENT RIDS TRANSPLANTATION SIDE EFFECTS.  // Worldwide Biotech;Jul2000, Vol. 12 Issue 7, p1 

    Reports on the treatment developed by scientists at Hadassah University Hospital and Enzo Biochem Inc. which reversed the side effects of a graft versus host disease in an individual receiving bone marrow stem cell transplantation.

  • Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemia. Kalhs, P; Brugger, S; Reiter, E; Keil, F; Fischer, G; Schulenburg, A; Rabitsch, W; Rosenmayr, A; Dieckmann, K; Kurz, M; Schwarzinger, I; Volc-Platzer, B; Mannhalter, C; Lechner, K; Greinix, H T // Bone Marrow Transplantation;4/15/99, Vol. 23 Issue 8, p753 

    Transplantation with unrelated donor (UD) marrow has been shown to potentially cure patients with leukemia. Between January 1991 and April 1998, 54 patients with leukemia have received an UD BMT at our institution. Five patients received their UD BMT as a second transplant after a preceding...

  • Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Chandy, M; Srivastava, A; Dennison, D; Mathews, V; George, B // Bone Marrow Transplantation;4/15/2001, Vol. 27 Issue 8, p785 

    We describe our experience of setting up an allogeneic BMT program at the Christian Medical College Hospital, Vellore over a period of 13 years, from October 1986 to December 1999. Two hundred and twenty-one transplants were performed during this period in 214 patients, with seven patients...

  • Blood: Mini-molecule governs severity of acute graft vs. host disease, study finds.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article offers information on a new research finding which led to the identification of new molecule which helps in controlling the severity of graft-versus- host disease in leukemia patients who have undergone bone marrow transplant.

  • Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group. Petterson, T. E.; Gabriel, M.; Tiedemann, K.; Teague, L.; Shaw, P. J.; Baker, D.; Bolton-Jones, R.; Tapp, H.; Oswald, C.; Vowels, M. R.; O'Brien, T. A. // Bone Marrow Transplantation;Feb2009, Vol. 43 Issue 3, p207 

    Unrelated umbilical cord blood (UCB) is an alternative stem cell source for paediatric patients lacking a matched related or unrelated marrow donor. We report the results of all paediatric unrelated UCB transplants performed in Australia and New Zealand over a 10-year period. A total of 135...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics